<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02286518</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-114/CPH-001</org_study_id>
    <secondary_id>U1111-1162-6078</secondary_id>
    <secondary_id>JapicCTI-142691</secondary_id>
    <nct_id>NCT02286518</nct_id>
  </id_info>
  <brief_title>TAK-114 Single- and Multiple-Dose Phase 1 Study</brief_title>
  <official_title>A Single-center, Single- and Multiple-Dose Phase 1 Study to Evaluate the Safety and Pharmacokinetics of TAK-114 in Healthy Adult Japanese and Caucasian Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of TAK-114 following
      single and multiple ascending oral doses in healthy Japanese male participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1, randomized, double-blind, placebo-controlled, single and multiple oral
      dose study in healthy Caucasian and Japanese male participants.

      The study is composed of three parts, Single-dose Ascending Part, Food Effect Part and
      Multiple-dose Ascending Part. Single-dose Ascending Part and Multiple-dose Ascending Part are
      designed as a randomized, double-blind or open-label, placebo-controlled, sequential-cohort,
      ascending single or multiple oral dose study of TAK-114 or matched placebo. The Food Effect
      Part is designed as a randomized, open-label, 2-period crossover study of a single dose of
      TAK-114.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE)</measure>
    <time_frame>Baseline up to 3 days after the last dose of study drug (Day 3 in Part 1), (Day 20 in Part 2) and 7 days after the last dose of study drug (Day 17 in Part 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With TEAEs Related to Vital Signs</measure>
    <time_frame>Baseline up to Day 3 in Part 1, Day 20 in Part 2 and Day 17 in Part 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With TEAEs Related to Body Weight</measure>
    <time_frame>Baseline up to Day 3 in Part 1, Day 20 in Part 2 and Day 17 in Part 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Meaningful Changes From Baseline in 12-lead Electrocardiograms (ECG)</measure>
    <time_frame>Baseline up to Day 3 in Part 1, Day 20 in Part 2 and Day 17 in Part 3</time_frame>
    <description>Number of participants who had ECG shifts from &quot;within normal limit&quot; at baseline to &quot;abnormal, clinically significant&quot; after study drug administration were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Meaningful Changes From Baseline in 12-lead Electrocardiograms (ECG)</measure>
    <time_frame>Baseline up to Day 2 (only for Cohorts 1A, 2A, and 3A) in Part 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Chemistry, Hematology or Urinalysis</measure>
    <time_frame>Baseline up to Day 3 in Part 1, Day 20 in Part 2 and Day 17 in Part 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax - Maximum Observed Plasma Concentration for TAK-114</measure>
    <time_frame>Day1: predose and at multiple time-points (up to 48 hours) postdose for Part 1; Day 1:predose and at multiple time-points (up to 48 hours) postdose in each period for Part 2; Day 10:predose and at multiple time points (up to 12 hours) postdose for Part 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-Infinity) - Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Unchanged TAK-114: Part 1 and Part 2</measure>
    <time_frame>Day 1: predose and at multiple time-points (up to 48 hours) postdose for Part 1; Day 1: predose and at multiple time-points (up to 48 hours) postdose in each period for Part 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-tau) - Area Under the Plasma Concentration-Time Curve From Time 0 to Time Tau for TAK-114: Part 3</measure>
    <time_frame>Day10: predose and at multiple time points (up to 12 hours) postdose for Part 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Terminal Phase Elimination Half-life (T1/2) for TAK-114</measure>
    <time_frame>Day1:predose and at multiple time-points (up to 48 hours) postdose for Part 1; Day1:predose and at multiple time-points (up to 48 hours) postdose in each period for Part 2; Day 10: predose and at multiple time points (up to 12 hours) postdose for Part 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean R(Cmax): Mean Accumulation Coefficient of Observed Maximum Plasma Concentration for TAK-114: Part 3</measure>
    <time_frame>Days 1 and 10: predose and at multiple time points (up to 12 hours) postdose for Part 3</time_frame>
    <description>Mean R(Cmax) was estimated as the ratio of Cmax on Day 10 and Cmax on Day 1. Cmax is the peak plasma drug concentration of TAK-114.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean R(AUC): Mean of Accumulation Coefficient of Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for TAK-114: Part 3</measure>
    <time_frame>Days 1 and 10: predose and at multiple time points (up to 12 hours) postdose for Part 3</time_frame>
    <description>Mean R(AUC) was estimated as the ratio of AUC(0-tau) on Day 10 and AUC(0-tau) on Day 1. AUC (0-tau) is the area under the plasma concentration-time curve from time 0 to time tau.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Excretion Ratio of TAK-114 From 0 to 48 Hours Postdose: Part 1</measure>
    <time_frame>Day 1: 0 to 48 hours postdose</time_frame>
    <description>Urinary excretion ratio (% of dose) of TAK-114 in urine were calculated for each participant. Ratio was calculated from the urine concentrations of each analyte and the volume of urine collected.</description>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Clinical Pharmacology</condition>
  <arm_group>
    <arm_group_label>Cohort 1A: TAK-114 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally, once only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1B: TAK-114 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally, once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2A: TAK-114 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally, once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2B: TAK-114 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally, once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3A: TAK-114 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally, once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3B: TAK-114 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally, once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4a: TAK-114 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Single-dose administration in a fasting state Period 2: Single-dose administration 30 minutes after breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4b: TAK-114 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Single-dose administration 30 minutes after breakfast Period 2: Single-dose administration in a fasting state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5A: TAK-114 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally, Twice daily, 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5B: TAK-114 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally, Twice daily, 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6A: TAK-114 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally, Twice daily, 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6B: TAK-114 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally, Twice daily, 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1A, 2A, 3A: TAK-114 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort 1A, 2A, 3A: Orally, once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5A: TAK-114 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort 5A: Orally, Twice daily, 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6A: TAK-114 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort 6A: Orally, Twice daily, 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-114 10 mg capsule</intervention_name>
    <arm_group_label>Cohort 1A: TAK-114 10 mg</arm_group_label>
    <arm_group_label>Cohort 1B: TAK-114 10 mg</arm_group_label>
    <arm_group_label>Cohort 2A: TAK-114 20 mg</arm_group_label>
    <arm_group_label>Cohort 2B: TAK-114 20 mg</arm_group_label>
    <arm_group_label>Cohort 3A: TAK-114 50 mg</arm_group_label>
    <arm_group_label>Cohort 3B: TAK-114 50 mg</arm_group_label>
    <arm_group_label>Cohort 4a: TAK-114 20 mg</arm_group_label>
    <arm_group_label>Cohort 4b: TAK-114 20 mg</arm_group_label>
    <arm_group_label>Cohort 5A: TAK-114 20 mg</arm_group_label>
    <arm_group_label>Cohort 5B: TAK-114 20 mg</arm_group_label>
    <arm_group_label>Cohort 6A: TAK-114 50 mg</arm_group_label>
    <arm_group_label>Cohort 6B: TAK-114 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-114 matched placebo</intervention_name>
    <arm_group_label>Cohort 1A, 2A, 3A: TAK-114 placebo</arm_group_label>
    <arm_group_label>Cohort 5A: TAK-114 placebo</arm_group_label>
    <arm_group_label>Cohort 6A: TAK-114 placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy Japanese participants:

          -  Must be willing to provide written informed consent and in the investigator's opinion
             able to comply with the study protocol.

          -  Is aged 20 to 45 years, inclusive.

          -  Weighs at least 50 kilogram (kg) and have a body mass index (BMI) between 18.5 and
             25.0 kilogram per square meter (kg/m^2).

        Healthy Caucasian participants:

          -  Must be willing to provide written informed consent and in the investigator's opinion
             able to comply with the study protocol.

          -  Is aged 20 to 45 years, inclusive; are of Caucasian descent (born to Caucasian parents
             and grandparents and has lived outside original country for less than 5 years) and
             maintains their original diet and lifestyle.

          -  Weighs at least 50 kg and have a body mass index between 18.5 and 30.0 kg/m2.

        Exclusion Criteria:

        • Participants have a known hypersensitivity to any component of the formulation of TAK-114
        or any herb medicine or supplement related to Indigo naturalis.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>General Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Sumida-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2014</study_first_submitted>
  <study_first_submitted_qc>November 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2014</study_first_posted>
  <results_first_submitted>April 27, 2016</results_first_submitted>
  <results_first_submitted_qc>June 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 25, 2016</results_first_posted>
  <last_update_submitted>June 13, 2016</last_update_submitted>
  <last_update_submitted_qc>June 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative site in Japan from 17 Nov 2014 to 29 April 2015.</recruitment_details>
      <pre_assignment_details>Healthy Japanese, Caucasian participants enrolled in study with 3 parts to receive TAK-114 single rising dose (SRD) (10 milligram [mg], 20 mg and 50 mg, once daily) in Part 1, TAK-114 20 mg in fasted and fed conditions, cross-over in Period 1 and 2 of food effect Part 2 and TAK-114 multiple rising dose (MRD) (20 mg, 50 mg twice daily) in Part 3.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1 SRD-Cohort 1A – 3A: Placebo</title>
          <description>TAK-114 placebo-matching capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
        </group>
        <group group_id="P2">
          <title>Part 1 SRD-Cohort 1A: TAK-114 10 mg</title>
          <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
        </group>
        <group group_id="P3">
          <title>Part 1 SRD-Cohort 2A: TAK-114 20 mg</title>
          <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
        </group>
        <group group_id="P4">
          <title>Part 1 SRD-Cohort 3A: TAK-114 50 mg</title>
          <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
        </group>
        <group group_id="P5">
          <title>Part 1 SRD - Cohort 1B : TAK-114 10 mg</title>
          <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
        </group>
        <group group_id="P6">
          <title>Part 1 SRD-Cohort 2B: TAK-114 20 mg</title>
          <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
        </group>
        <group group_id="P7">
          <title>Part 1 SRD-Cohort 3B: TAK-114 50 mg</title>
          <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
        </group>
        <group group_id="P8">
          <title>Part 2- Cohort 4: TAK-114 Fasted + TAK-114Fed</title>
          <description>TAK-114 20 mg, capsule, orally, in fasted condition, once on Day 1 of Period 1 (3 days), followed by 14 days washout period, followed by TAK-114 20 mg, capsule, orally, in fed condition (after food), once on Day 1 of Period 2 (3 days), in Japanese participants.</description>
        </group>
        <group group_id="P9">
          <title>Part 2 Cohort 4: TAK-114 Fed + TAK-114 Fasted</title>
          <description>TAK-114 20 mg, capsule, orally, in fed condition (after food), once on Day 1 of Period 2 (3 days), followed by 14 days washout period, followed by TAK-114 20 mg, capsule, orally, in fasted condition, once on Day 1 of Period 2 (3 days), in Japanese participants.</description>
        </group>
        <group group_id="P10">
          <title>Part 3 Placebo Cohort 5A – 6A: Placebo</title>
          <description>TAK-114 placebo-matching, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
        </group>
        <group group_id="P11">
          <title>Part 3 Cohort 5A MRD: TAK-114 20 mg</title>
          <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
        </group>
        <group group_id="P12">
          <title>Part 3 Cohort 6A MRD: TAK-114 50 mg</title>
          <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
        </group>
        <group group_id="P13">
          <title>Part 3 Cohort 5B MRD: TAK-114 20 mg</title>
          <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
        </group>
        <group group_id="P14">
          <title>Part 3 Cohort 6B MRD: TAK-114 50 mg</title>
          <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>All Parts (16 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="6"/>
                <participants group_id="P14" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6">Participants from Part 1 and 3 did not continued in the washout period of Part 2 (crossover part).</participants>
                <participants group_id="P2" count="6">Participants from Part 1 and 3 did not continued in the washout period of Part 2 (crossover part).</participants>
                <participants group_id="P3" count="6">Participants from Part 1 and 3 did not continued in the washout period of Part 2 (crossover part).</participants>
                <participants group_id="P4" count="6">Participants from Part 1 and 3 did not continued in the washout period of Part 2 (crossover part).</participants>
                <participants group_id="P5" count="6">Participants from Part 1 and 3 did not continued in the washout period of Part 2 (crossover part).</participants>
                <participants group_id="P6" count="6">Participants from Part 1 and 3 did not continued in the washout period of Part 2 (crossover part).</participants>
                <participants group_id="P7" count="6">Participants from Part 1 and 3 did not continued in the washout period of Part 2 (crossover part).</participants>
                <participants group_id="P8" count="6">Only participants of Part 2 continued in next period.</participants>
                <participants group_id="P9" count="6">Only participants of Part 2 would continue in next period.</participants>
                <participants group_id="P10" count="4">Participants from Part 1 and 3 did not continued in the washout period of Part 2 (crossover part).</participants>
                <participants group_id="P11" count="6">Participants from Part 1 and 3 did not continued in the washout period of Part 2 (crossover part).</participants>
                <participants group_id="P12" count="6">Participants from Part 1 and 3 did not continued in the washout period of Part 2 (crossover part).</participants>
                <participants group_id="P13" count="6">Participants from Part 1 and 3 did not continued in the washout period of Part 2 (crossover part).</participants>
                <participants group_id="P14" count="6">Participants from Part 1 and 3 did not continued in the washout period of Part 2 (crossover part).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Crossover Period(Part 2:14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Crossover Treatment (Part 2: 3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety analysis set was defined as all participants who were enrolled and completed the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Part 1 SRD-Cohort 1A – 3A: Placebo</title>
          <description>TAK-114 placebo-matching capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
        </group>
        <group group_id="B2">
          <title>Part 1 SRD-Cohort 1A: TAK-114 10 mg</title>
          <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
        </group>
        <group group_id="B3">
          <title>Part 1 SRD-Cohort 2A: TAK-114 20 mg</title>
          <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
        </group>
        <group group_id="B4">
          <title>Part 1 SRD-Cohort 3A: TAK-114 50 mg</title>
          <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
        </group>
        <group group_id="B5">
          <title>Part 1 SRD - Cohort 1B : TAK-114 10 mg</title>
          <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
        </group>
        <group group_id="B6">
          <title>Part 1 SRD-Cohort 2B: TAK-114 20 mg</title>
          <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
        </group>
        <group group_id="B7">
          <title>Part 1 SRD-Cohort 3B: TAK-114 50 mg</title>
          <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
        </group>
        <group group_id="B8">
          <title>Part 2- Cohort 4: TAK-114 Fasted + TAK-114Fed</title>
          <description>TAK-114 20 mg, capsule, orally, in fasted condition, once on Day 1 of Period 1 (3 days), followed by 14 days washout period, followed by TAK-114 20 mg, capsule, orally, in fed condition (after food), once on Day 1 of Period 2 (3 days), in Japanese participants.</description>
        </group>
        <group group_id="B9">
          <title>Part 2 Cohort 4: TAK-114 20 mg Fed + TAK-114 20 mg Fasted</title>
          <description>TAK-114 20 mg, capsule, orally, once on Day 1, fed state in period 2 (3 days), followed by a 14 day washout period, further followed by TAK-114 20 mg, capsule, orally, once on Day 1 in fasted state in period 1, in healthy Japanese participants.</description>
        </group>
        <group group_id="B10">
          <title>Part 3 Placebo Cohort 5A – 6A: Placebo</title>
          <description>TAK-114 placebo-matching, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
        </group>
        <group group_id="B11">
          <title>Part 3 Cohort 5A MRD: TAK-114 20 mg</title>
          <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
        </group>
        <group group_id="B12">
          <title>Part 3 Cohort 6A MRD: TAK-114 50 mg</title>
          <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
        </group>
        <group group_id="B13">
          <title>Part 3 Cohort 5B MRD: TAK-114 20 mg</title>
          <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
        </group>
        <group group_id="B14">
          <title>Part 3 Cohort 6B MRD: TAK-114 50 mg</title>
          <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
        </group>
        <group group_id="B15">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="4"/>
            <count group_id="B11" value="6"/>
            <count group_id="B12" value="6"/>
            <count group_id="B13" value="6"/>
            <count group_id="B14" value="6"/>
            <count group_id="B15" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.5" spread="8.48"/>
                    <measurement group_id="B2" value="29.8" spread="7.25"/>
                    <measurement group_id="B3" value="28.3" spread="10.27"/>
                    <measurement group_id="B4" value="34.2" spread="10.26"/>
                    <measurement group_id="B5" value="32.0" spread="7.24"/>
                    <measurement group_id="B6" value="30.3" spread="5.65"/>
                    <measurement group_id="B7" value="26.3" spread="4.97"/>
                    <measurement group_id="B8" value="25.5" spread="3.51"/>
                    <measurement group_id="B9" value="35.3" spread="8.12"/>
                    <measurement group_id="B10" value="41.0" spread="4.08"/>
                    <measurement group_id="B11" value="30.3" spread="9.22"/>
                    <measurement group_id="B12" value="33.7" spread="10.73"/>
                    <measurement group_id="B13" value="29.3" spread="5.54"/>
                    <measurement group_id="B14" value="33.2" spread="5.74"/>
                    <measurement group_id="B15" value="31.3" spread="7.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <description>All participants enrolled in the study were male.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Classification</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Drinks Every Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drinks a Few Days per Week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="5"/>
                    <measurement group_id="B14" value="4"/>
                    <measurement group_id="B15" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drinks a Few Days per Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Does not drink</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Caffeine Classification</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caffeine Consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="5"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Caffeine Consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="4"/>
                    <measurement group_id="B15" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE)</title>
        <time_frame>Baseline up to 3 days after the last dose of study drug (Day 3 in Part 1), (Day 20 in Part 2) and 7 days after the last dose of study drug (Day 17 in Part 3)</time_frame>
        <population>The safety analysis set includes all participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 SRD-Cohort 1A – 3A: Placebo</title>
            <description>TAK-114 placebo-matching capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 SRD-Cohort 1A: TAK-114 10 mg</title>
            <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 SRD-Cohort 2A: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 SRD-Cohort 3A: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 SRD - Cohort 1B : TAK-114 10 mg</title>
            <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 SRD-Cohort 2B: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 SRD-Cohort 3B: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O8">
            <title>Part 2 Cohort 4: TAK-114 20 mg Fasted</title>
            <description>TAK-114 20 mg, capsule, orally, in fasted condition, once on Day 1 of either Period 1 or 2 of 3 days, in Japanese participants.</description>
          </group>
          <group group_id="O9">
            <title>Part 2 Cohort 4: TAK-114 20 mg Fed</title>
            <description>TAK-114 20 mg, capsule, orally, in fed condition (after food), once on Day 1 of either Period 1 or 2 of 3 days, in Japanese participants.</description>
          </group>
          <group group_id="O10">
            <title>Part 3 Placebo Cohort 5A – 6A: Placebo</title>
            <description>TAK-114 placebo-matching, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O11">
            <title>Part 3 Cohort 5A MRD: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O12">
            <title>Part 3 Cohort 6A MRD: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O13">
            <title>Part 3 Cohort 5B MRD: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O14">
            <title>Part 3 Cohort 6B MRD: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE)</title>
          <population>The safety analysis set includes all participants who received the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="5"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With TEAEs Related to Vital Signs</title>
        <time_frame>Baseline up to Day 3 in Part 1, Day 20 in Part 2 and Day 17 in Part 3</time_frame>
        <population>The safety analysis set includes all participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 SRD-Cohort 1A – 3A: Placebo</title>
            <description>TAK-114 placebo-matching capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 SRD-Cohort 1A: TAK-114 10 mg</title>
            <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 SRD-Cohort 2A: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 SRD-Cohort 3A: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 SRD - Cohort 1B : TAK-114 10 mg</title>
            <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 SRD-Cohort 2B: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 SRD-Cohort 3B: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O8">
            <title>Part 2 Cohort 4: TAK-114 20 mg Fasted</title>
            <description>TAK-114 20 mg, capsule, orally, in fasted condition, once on Day 1 of either Period 1 or 2 of 3 days, in Japanese participants.</description>
          </group>
          <group group_id="O9">
            <title>Part 2 Cohort 4: TAK-114 20 mg Fed</title>
            <description>TAK-114 20 mg, capsule, orally, in fed condition (after food), once on Day 1 of either Period 1 or 2 of 3 days, in Japanese participants.</description>
          </group>
          <group group_id="O10">
            <title>Part 3 Placebo Cohort 5A – 6A: Placebo</title>
            <description>TAK-114 placebo-matching, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O11">
            <title>Part 3 Cohort 5A MRD: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O12">
            <title>Part 3 Cohort 6A MRD: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O13">
            <title>Part 3 Cohort 5B MRD: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O14">
            <title>Part 3 Cohort 6B MRD: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs Related to Vital Signs</title>
          <population>The safety analysis set includes all participants who received the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With TEAEs Related to Body Weight</title>
        <time_frame>Baseline up to Day 3 in Part 1, Day 20 in Part 2 and Day 17 in Part 3</time_frame>
        <population>The safety analysis set includes all participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 SRD-Cohort 1A – 3A: Placebo</title>
            <description>TAK-114 placebo-matching capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 SRD-Cohort 1A: TAK-114 10 mg</title>
            <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 SRD-Cohort 2A: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 SRD-Cohort 3A: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 SRD - Cohort 1B : TAK-114 10 mg</title>
            <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 SRD-Cohort 2B: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 SRD-Cohort 3B: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O8">
            <title>Part 2 Cohort 4: TAK-114 20 mg Fasted</title>
            <description>TAK-114 20 mg, capsule, orally, in fasted condition, once on Day 1 of either Period 1 or 2 of 3 days, in Japanese participants.</description>
          </group>
          <group group_id="O9">
            <title>Part 2 Cohort 4: TAK-114 20 mg Fed</title>
            <description>TAK-114 20 mg, capsule, orally, in fed condition (after food), once on Day 1 of either Period 1 or 2 of 3 days, in Japanese participants.</description>
          </group>
          <group group_id="O10">
            <title>Part 3 Placebo Cohort 5A – 6A: Placebo</title>
            <description>TAK-114 placebo-matching, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O11">
            <title>Part 3 Cohort 5A MRD: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O12">
            <title>Part 3 Cohort 6A MRD: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O13">
            <title>Part 3 Cohort 5B MRD: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O14">
            <title>Part 3 Cohort 6B MRD: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs Related to Body Weight</title>
          <population>The safety analysis set includes all participants who received the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Meaningful Changes From Baseline in 12-lead Electrocardiograms (ECG)</title>
        <description>Number of participants who had ECG shifts from “within normal limit” at baseline to “abnormal, clinically significant” after study drug administration were reported.</description>
        <time_frame>Baseline up to Day 3 in Part 1, Day 20 in Part 2 and Day 17 in Part 3</time_frame>
        <population>The safety analysis set includes all participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 SRD-Cohort 1A – 3A: Placebo</title>
            <description>TAK-114 placebo-matching capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 SRD-Cohort 1A: TAK-114 10 mg</title>
            <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 SRD-Cohort 2A: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 SRD-Cohort 3A: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 SRD - Cohort 1B : TAK-114 10 mg</title>
            <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 SRD-Cohort 2B: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 SRD-Cohort 3B: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O8">
            <title>Part 2 Cohort 4: TAK-114 20 mg Fasted</title>
            <description>TAK-114 20 mg, capsule, orally, in fasted condition, once on Day 1 of either Period 1 or 2 of 3 days, in Japanese participants.</description>
          </group>
          <group group_id="O9">
            <title>Part 2 Cohort 4: TAK-114 20 mg Fed</title>
            <description>TAK-114 20 mg, capsule, orally, in fed condition (after food), once on Day 1 of either Period 1 or 2 of 3 days, in Japanese participants.</description>
          </group>
          <group group_id="O10">
            <title>Part 3 Placebo Cohort 5A – 6A: Placebo</title>
            <description>TAK-114 placebo-matching, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O11">
            <title>Part 3 Cohort 5A MRD: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O12">
            <title>Part 3 Cohort 6A MRD: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O13">
            <title>Part 3 Cohort 5B MRD: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O14">
            <title>Part 3 Cohort 6B MRD: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Meaningful Changes From Baseline in 12-lead Electrocardiograms (ECG)</title>
          <description>Number of participants who had ECG shifts from “within normal limit” at baseline to “abnormal, clinically significant” after study drug administration were reported.</description>
          <population>The safety analysis set includes all participants who received the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Meaningful Changes From Baseline in 12-lead Electrocardiograms (ECG)</title>
        <time_frame>Baseline up to Day 2 (only for Cohorts 1A, 2A, and 3A) in Part 1</time_frame>
        <population>The safety analysis set includes all participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 SRD-Cohort 1A – 3A: Placebo</title>
            <description>TAK-114 placebo-matching capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 SRD-Cohort 1A: TAK-114 10 mg</title>
            <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 SRD-Cohort 2A: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 SRD-Cohort 3A: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Meaningful Changes From Baseline in 12-lead Electrocardiograms (ECG)</title>
          <population>The safety analysis set includes all participants who received the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Chemistry, Hematology or Urinalysis</title>
        <time_frame>Baseline up to Day 3 in Part 1, Day 20 in Part 2 and Day 17 in Part 3</time_frame>
        <population>The safety analysis set includes all participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 SRD-Cohort 1A – 3A: Placebo</title>
            <description>TAK-114 placebo-matching capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 SRD-Cohort 1A: TAK-114 10 mg</title>
            <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 SRD-Cohort 2A: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 SRD-Cohort 3A: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 SRD - Cohort 1B : TAK-114 10 mg</title>
            <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 SRD-Cohort 2B: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 SRD-Cohort 3B: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O8">
            <title>Part 2 Cohort 4: TAK-114 20 mg Fasted</title>
            <description>TAK-114 20 mg, capsule, orally, in fasted condition, once on Day 1 of either Period 1 or 2 of 3 days, in Japanese participants.</description>
          </group>
          <group group_id="O9">
            <title>Part 2 Cohort 4: TAK-114 20 mg Fed</title>
            <description>TAK-114 20 mg, capsule, orally, in fed condition (after food), once on Day 1 of either Period 1 or 2 of 3 days, in Japanese participants.</description>
          </group>
          <group group_id="O10">
            <title>Part 3 Placebo Cohort 5A – 6A: Placebo</title>
            <description>TAK-114 placebo-matching, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O11">
            <title>Part 3 Cohort 5A MRD: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O12">
            <title>Part 3 Cohort 6A MRD: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O13">
            <title>Part 3 Cohort 5B MRD: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O14">
            <title>Part 3 Cohort 6B MRD: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Chemistry, Hematology or Urinalysis</title>
          <population>The safety analysis set includes all participants who received the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C-reactive protein increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cell count increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine aminotransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood triglycerides increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoglobin decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High density lipoprotein decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax - Maximum Observed Plasma Concentration for TAK-114</title>
        <time_frame>Day1: predose and at multiple time-points (up to 48 hours) postdose for Part 1; Day 1:predose and at multiple time-points (up to 48 hours) postdose in each period for Part 2; Day 10:predose and at multiple time points (up to 12 hours) postdose for Part 3</time_frame>
        <population>The Pharmacokinetic (PK) analysis set includes all participants who had received the study drug and met the essential requirements defined in the study protocol without any critical protocol violations, and in whom PK assessment was possible.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 SRD-Cohort 1A: TAK-114 10 mg</title>
            <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 SRD-Cohort 2A: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 SRD-Cohort 3A: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 SRD - Cohort 1B : TAK-114 10 mg</title>
            <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 SRD-Cohort 2B: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 SRD-Cohort 3B: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O7">
            <title>Part 2 Cohort 4: TAK-114 20 mg Fasted</title>
            <description>TAK-114 20 mg, capsule, orally, in fasted condition, once on Day 1 of either Period 1 or 2 of 3 days, in Japanese participants.</description>
          </group>
          <group group_id="O8">
            <title>Part 2 Cohort 4: TAK-114 20 mg Fed</title>
            <description>TAK-114 20 mg, capsule, orally, in fed condition (after food), once on Day 1 of either Period 1 or 2 of 3 days, in Japanese participants.</description>
          </group>
          <group group_id="O9">
            <title>Part 3 Cohort 5A MRD: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O10">
            <title>Part 3 Cohort 6A MRD: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O11">
            <title>Part 3 Cohort 5B MRD: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O12">
            <title>Part 3 Cohort 6B MRD: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Maximum Observed Plasma Concentration for TAK-114</title>
          <population>The Pharmacokinetic (PK) analysis set includes all participants who had received the study drug and met the essential requirements defined in the study protocol without any critical protocol violations, and in whom PK assessment was possible.</population>
          <units>picogram per milliliter (pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.15" spread="10.051"/>
                    <measurement group_id="O2" value="68.74" spread="26.789"/>
                    <measurement group_id="O3" value="168.1" spread="71.210"/>
                    <measurement group_id="O4" value="30.98" spread="14.822"/>
                    <measurement group_id="O5" value="74.72" spread="17.886"/>
                    <measurement group_id="O6" value="140.8" spread="47.499"/>
                    <measurement group_id="O7" value="98.12" spread="34.944"/>
                    <measurement group_id="O8" value="150.8" spread="56.655"/>
                    <measurement group_id="O9" value="39.37" spread="4.8430"/>
                    <measurement group_id="O10" value="112.6" spread="12.857"/>
                    <measurement group_id="O11" value="24.53" spread="7.1949"/>
                    <measurement group_id="O12" value="106.7" spread="36.967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (0-Infinity) - Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Unchanged TAK-114: Part 1 and Part 2</title>
        <time_frame>Day 1: predose and at multiple time-points (up to 48 hours) postdose for Part 1; Day 1: predose and at multiple time-points (up to 48 hours) postdose in each period for Part 2</time_frame>
        <population>The Pharmacokinetic (PK) analysis set includes all participants who had received the study drug and met the essential requirements defined in the study protocol without any critical protocol violations, and in whom PK assessment was possible.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 SRD-Cohort 1A: TAK-114 10 mg</title>
            <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 SRD-Cohort 2A: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 SRD-Cohort 3A: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 SRD - Cohort 1B : TAK-114 10 mg</title>
            <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 SRD-Cohort 2B: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 SRD-Cohort 3B: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O7">
            <title>Part 2 Cohort 4: TAK-114 20 mg Fasted</title>
            <description>TAK-114 20 mg, capsule, orally, in fasted condition, once on Day 1 of either Period 1 or 2 of 3 days, in Japanese participants.</description>
          </group>
          <group group_id="O8">
            <title>Part 2 Cohort 4: TAK-114 20 mg Fed</title>
            <description>TAK-114 20 mg, capsule, orally, in fed condition (after food), once on Day 1 of either Period 1 or 2 of 3 days, in Japanese participants.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-Infinity) - Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Unchanged TAK-114: Part 1 and Part 2</title>
          <population>The Pharmacokinetic (PK) analysis set includes all participants who had received the study drug and met the essential requirements defined in the study protocol without any critical protocol violations, and in whom PK assessment was possible.</population>
          <units>picogram*hour per milliliter (pg*hr/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="469.2" spread="112.44"/>
                    <measurement group_id="O2" value="762.2" spread="195.14"/>
                    <measurement group_id="O3" value="1708" spread="607.24"/>
                    <measurement group_id="O4" value="472.3" spread="77.694"/>
                    <measurement group_id="O5" value="879.2" spread="142.15"/>
                    <measurement group_id="O6" value="2180" spread="405.22"/>
                    <measurement group_id="O7" value="918.9" spread="165.75"/>
                    <measurement group_id="O8" value="918.2" spread="197.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (0-tau) - Area Under the Plasma Concentration-Time Curve From Time 0 to Time Tau for TAK-114: Part 3</title>
        <time_frame>Day10: predose and at multiple time points (up to 12 hours) postdose for Part 3</time_frame>
        <population>The Pharmacokinetic (PK) analysis set includes all participants who had received the study drug and met the essential requirements defined in the study protocol without any critical protocol violations, and in whom PK assessment was possible.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3 Cohort 5A MRD: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Part 3 Cohort 6A MRD: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Part 3 Cohort 5B MRD: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O4">
            <title>Part 3 Cohort 6B MRD: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-tau) - Area Under the Plasma Concentration-Time Curve From Time 0 to Time Tau for TAK-114: Part 3</title>
          <population>The Pharmacokinetic (PK) analysis set includes all participants who had received the study drug and met the essential requirements defined in the study protocol without any critical protocol violations, and in whom PK assessment was possible.</population>
          <units>pg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251.3" spread="47.209"/>
                    <measurement group_id="O2" value="838.0" spread="140.39"/>
                    <measurement group_id="O3" value="183.2" spread="49.061"/>
                    <measurement group_id="O4" value="749.7" spread="243.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Terminal Phase Elimination Half-life (T1/2) for TAK-114</title>
        <time_frame>Day1:predose and at multiple time-points (up to 48 hours) postdose for Part 1; Day1:predose and at multiple time-points (up to 48 hours) postdose in each period for Part 2; Day 10: predose and at multiple time points (up to 12 hours) postdose for Part 3</time_frame>
        <population>The Pharmacokinetic (PK) analysis set includes all participants who had received the study drug and met the essential requirements defined in the study protocol without any critical protocol violations, and in whom PK assessment was possible.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 SRD-Cohort 1A: TAK-114 10 mg</title>
            <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 SRD-Cohort 2A: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 SRD-Cohort 3A: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 SRD - Cohort 1B : TAK-114 10 mg</title>
            <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 SRD-Cohort 2B: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 SRD-Cohort 3B: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O7">
            <title>Part 2 Cohort 4: TAK-114 20 mg Fasted</title>
            <description>TAK-114 20 mg, capsule, orally, in fasted condition, once on Day 1 of either Period 1 or 2 of 3 days, in Japanese participants.</description>
          </group>
          <group group_id="O8">
            <title>Part 2 Cohort 4: TAK-114 20 mg Fed</title>
            <description>TAK-114 20 mg, capsule, orally, in fed condition (after food), once on Day 1 of either Period 1 or 2 of 3 days, in Japanese participants.</description>
          </group>
          <group group_id="O9">
            <title>Part 3 Cohort 5A MRD: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O10">
            <title>Part 3 Cohort 6A MRD: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O11">
            <title>Part 3 Cohort 5B MRD: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O12">
            <title>Part 3 Cohort 6B MRD: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Terminal Phase Elimination Half-life (T1/2) for TAK-114</title>
          <population>The Pharmacokinetic (PK) analysis set includes all participants who had received the study drug and met the essential requirements defined in the study protocol without any critical protocol violations, and in whom PK assessment was possible.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.108" spread="0.76763"/>
                    <measurement group_id="O2" value="5.500" spread="2.7925"/>
                    <measurement group_id="O3" value="5.272" spread="2.0918"/>
                    <measurement group_id="O4" value="7.417" spread="1.9012"/>
                    <measurement group_id="O5" value="5.822" spread="0.75503"/>
                    <measurement group_id="O6" value="6.213" spread="1.0856"/>
                    <measurement group_id="O7" value="4.294" spread="1.0600"/>
                    <measurement group_id="O8" value="3.705" spread="1.1044"/>
                    <measurement group_id="O9" value="4.972" spread="1.6574"/>
                    <measurement group_id="O10" value="6.970" spread="1.0813"/>
                    <measurement group_id="O11" value="6.045" spread="2.2456"/>
                    <measurement group_id="O12" value="7.283" spread="2.2407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean R(Cmax): Mean Accumulation Coefficient of Observed Maximum Plasma Concentration for TAK-114: Part 3</title>
        <description>Mean R(Cmax) was estimated as the ratio of Cmax on Day 10 and Cmax on Day 1. Cmax is the peak plasma drug concentration of TAK-114.</description>
        <time_frame>Days 1 and 10: predose and at multiple time points (up to 12 hours) postdose for Part 3</time_frame>
        <population>The Pharmacokinetic (PK) analysis set includes all participants who had received the study drug and met the essential requirements defined in the study protocol without any critical protocol violations, and in whom PK assessment was possible.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3 Cohort 5A MRD: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Part 3 Cohort 6A MRD: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Part 3 Cohort 5B MRD: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O4">
            <title>Part 3 Cohort 6B MRD: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean R(Cmax): Mean Accumulation Coefficient of Observed Maximum Plasma Concentration for TAK-114: Part 3</title>
          <description>Mean R(Cmax) was estimated as the ratio of Cmax on Day 10 and Cmax on Day 1. Cmax is the peak plasma drug concentration of TAK-114.</description>
          <population>The Pharmacokinetic (PK) analysis set includes all participants who had received the study drug and met the essential requirements defined in the study protocol without any critical protocol violations, and in whom PK assessment was possible.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2368" spread="0.05638"/>
                    <measurement group_id="O2" value="0.3606" spread="0.10037"/>
                    <measurement group_id="O3" value="0.2125" spread="0.06181"/>
                    <measurement group_id="O4" value="0.3190" spread="0.06630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean R(AUC): Mean of Accumulation Coefficient of Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for TAK-114: Part 3</title>
        <description>Mean R(AUC) was estimated as the ratio of AUC(0-tau) on Day 10 and AUC(0-tau) on Day 1. AUC (0-tau) is the area under the plasma concentration-time curve from time 0 to time tau.</description>
        <time_frame>Days 1 and 10: predose and at multiple time points (up to 12 hours) postdose for Part 3</time_frame>
        <population>The Pharmacokinetic (PK) analysis set includes all participants who had received the study drug and met the essential requirements defined in the study protocol without any critical protocol violations, and in whom PK assessment was possible.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3 Cohort 5A MRD: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Part 3 Cohort 6A MRD: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Part 3 Cohort 5B MRD: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O4">
            <title>Part 3 Cohort 6B MRD: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean R(AUC): Mean of Accumulation Coefficient of Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for TAK-114: Part 3</title>
          <description>Mean R(AUC) was estimated as the ratio of AUC(0-tau) on Day 10 and AUC(0-tau) on Day 1. AUC (0-tau) is the area under the plasma concentration-time curve from time 0 to time tau.</description>
          <population>The Pharmacokinetic (PK) analysis set includes all participants who had received the study drug and met the essential requirements defined in the study protocol without any critical protocol violations, and in whom PK assessment was possible.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3032" spread="0.07024"/>
                    <measurement group_id="O2" value="0.4768" spread="0.15749"/>
                    <measurement group_id="O3" value="0.3128" spread="0.08596"/>
                    <measurement group_id="O4" value="0.4087" spread="0.04966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Excretion Ratio of TAK-114 From 0 to 48 Hours Postdose: Part 1</title>
        <description>Urinary excretion ratio (% of dose) of TAK-114 in urine were calculated for each participant. Ratio was calculated from the urine concentrations of each analyte and the volume of urine collected.</description>
        <time_frame>Day 1: 0 to 48 hours postdose</time_frame>
        <population>The Pharmacokinetic (PK) analysis set includes all participants who had received the study drug and met the essential requirements defined in the study protocol without any critical protocol violations, and in whom PK assessment was possible.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 SRD-Cohort 1A: TAK-114 10 mg</title>
            <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 SRD-Cohort 2A: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 SRD-Cohort 3A: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 SRD - Cohort 1B : TAK-114 10 mg</title>
            <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 SRD-Cohort 2B: TAK-114 20 mg</title>
            <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 SRD-Cohort 3B: TAK-114 50 mg</title>
            <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Excretion Ratio of TAK-114 From 0 to 48 Hours Postdose: Part 1</title>
          <description>Urinary excretion ratio (% of dose) of TAK-114 in urine were calculated for each participant. Ratio was calculated from the urine concentrations of each analyte and the volume of urine collected.</description>
          <population>The Pharmacokinetic (PK) analysis set includes all participants who had received the study drug and met the essential requirements defined in the study protocol without any critical protocol violations, and in whom PK assessment was possible.</population>
          <units>percentage of dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003835" spread="0.0019990"/>
                    <measurement group_id="O2" value="0.001984" spread="0.00055667"/>
                    <measurement group_id="O3" value="0.002759" spread="0.0017349"/>
                    <measurement group_id="O4" value="0.003724" spread="0.0022022"/>
                    <measurement group_id="O5" value="0.003143" spread="0.00083500"/>
                    <measurement group_id="O6" value="0.002420" spread="0.0012154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events are adverse events that started after first dose of study drug and no more 3 days after the last dose of study drug (Day 3 in Part 1), (Day 20 in Part 2) and 7 days after the last dose of study drug (Day 17 in Part 3).</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1 SRD-Cohort 1A – 3A: Placebo</title>
          <description>TAK-114 placebo-matching capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
        </group>
        <group group_id="E2">
          <title>Part 1 SRD-Cohort 1A: TAK-114 10 mg</title>
          <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
        </group>
        <group group_id="E3">
          <title>Part 1 SRD-Cohort 2A: TAK-114 20 mg</title>
          <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
        </group>
        <group group_id="E4">
          <title>Part 1 SRD-Cohort 3A: TAK-114 50 mg</title>
          <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Japanese participants.</description>
        </group>
        <group group_id="E5">
          <title>Part 1 SRD - Cohort 1B : TAK-114 10 mg</title>
          <description>TAK-114 10 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
        </group>
        <group group_id="E6">
          <title>Part 1 SRD-Cohort 2B: TAK-114 20 mg</title>
          <description>TAK-114 20 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
        </group>
        <group group_id="E7">
          <title>Part 1 SRD-Cohort 3B: TAK-114 50 mg</title>
          <description>TAK-114 50 mg, capsule, orally, once on Day 1 in the 3 days treatment period, in Caucasian participants.</description>
        </group>
        <group group_id="E8">
          <title>Part 2 Cohort 4: TAK-114 20 mg Fasted</title>
          <description>TAK-114 20 mg, capsule, orally, in fasted condition, once on Day 1 of either Period 1 or 2 of 3 days, in Japanese participants.</description>
        </group>
        <group group_id="E9">
          <title>Part 2 Cohort 4: TAK-114 20 mg Fed</title>
          <description>TAK-114 20 mg, capsule, orally, in fed condition (after food), once on Day 1 of either Period 1 or 2 of 3 days, in Japanese participants.</description>
        </group>
        <group group_id="E10">
          <title>Part 3 Placebo Cohort 5A – 6A: Placebo</title>
          <description>TAK-114 placebo-matching, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
        </group>
        <group group_id="E11">
          <title>Part 3 Cohort 5A MRD: TAK-114 20 mg</title>
          <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
        </group>
        <group group_id="E12">
          <title>Part 3 Cohort 6A MRD: TAK-114 50 mg</title>
          <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Japanese participants.</description>
        </group>
        <group group_id="E13">
          <title>Part 3 Cohort 5B MRD: TAK-114 20 mg</title>
          <description>TAK-114 20 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
        </group>
        <group group_id="E14">
          <title>Part 3 Cohort 6B MRD: TAK-114 50 mg</title>
          <description>TAK-114 50 mg, capsule, orally, twice daily on Days 1-9 and once only in the morning of Day 10 of the 10 days treatment period, in Caucasian participants.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>High density lipoprotein decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="5" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda’s sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

